GT Biopharma surges as FDA clears human trial for new cancer drug

Shares of drug developer  GT Biopharma GTBP.O rise 17.9% to $0.60 premarket

 Co says U.S. FDA cleared human testing of its experimental drug GTB‑5550 for advanced cancers

 Drug aims to help immune cells attack tumors that carry B7‑H3, a protein seen in prostate, ovarian, pancreatic and other solid cancers, per co

 Early study will test safety using short treatment cycles and multiple dose levels; co plans to expand to up to seven cancers after safety checks - GTBP

Shares down ~74% in 2025